Reviews published in Kidney Research and Clinical Practice and the American Journal of Preventive Cardiology highlight the growing evidence supporting the use of GLP-1 receptor agonists in managing diabetic kidney disease and emphasize their potential to improve both kidney and heart health in patients with T2DM
It is important to note that retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains under clinical investigation
Thats coming to an end: The FDA declared the tirzepatide shortage over in December and did the same for the semaglutide shortage in February
There are also a few cautions the FDA notes specific to this drug, including but not limited to: risk of pancreatitis hypoglycemia (low blood sugar) when used in conjunction with certain other drugs renal impairment or kidney failure acute gallbladder disease increased risk of thyroid C-cell tumors The FDA notes that patients who have had, or have family members who have had, medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use liraglutide, nor should individuals who have experienced prior serious hypersensitivity reaction to the drug
These treatments work by enhancing your bodys natural hunger and blood sugar signals to help you: Feel full sooner Stay satisfied longer Reduce cravings Improve blood sugar control Support steady, sustainable weight loss Built for Convenience Taken once per day Can be taken in the morning or evening No refrigeration required Delivered directly to you How the Tablet Works Dissolves in 30 to 60 seconds Absorbed through the mouth and digestive tract No large pills to swallow Guided by Your Rejuvime Team Medication access is provided as part of your Rejuvime service membership Dosing tailored to your goals and tolerance Gradual dose adjustments to improve comfort Ongoing monitoring and follow up Unlike injectable GLP-1 medications, oral options are taken as a daily tablet, making them a great choice for patients who prefer to avoid injections
[1] Patients considering any modification to standard dosing regimens should discuss this thoroughly with their GP or endocrinologist, as unsupervised dose adjustments may compromise treatment effectiveness and safety
